RT Journal Article
SR Electronic
T1 Clade I Mpox virus genomic diversity in the Democratic Republic of the Congo, 2018 - 2024: Predominance of Zoonotic Transmission
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.08.13.24311951
DO 10.1101/2024.08.13.24311951
A1 Kinganda-Lusamaki, Eddy
A1 Amuri-Aziza, Adrienne
A1 Fernandez, Nicolas
A1 Makangara-Cigolo, Jean-Claude
A1 Pratt, Catherine
A1 Hasivirwe Vakaniaki, Emmanuel
A1 Hoff, Nicole A.
A1 Luakanda, Gradi
A1 Akil-Bandali, Prince
A1 Sabiti Nundu, Sabin
A1 Mulopo-Mukanya, Noella
A1 Ngimba, Michel
A1 Modadra-Madakpa, Brigitte
A1 Diavita, Ruth
A1 Paku, Princesse
A1 Pukuta-Simbu, Elisabeth
A1 Merritt, Sydney
A1 O’Toole, Áine
A1 Low, Nicola
A1 Nkuba-Ndaye, Antoine
A1 Kavunga-Membo, Hugo
A1 Shongo, Robert
A1 Liesenborghs, Laurens
A1 Wawina-Bokalanga, Tony
A1 Vercauteren, Koen
A1 Mukadi-Bamuleka, Daniel
A1 Subissi, Lorenzo
A1 Muyembe, Jean-Jacques
A1 Kindrachuk, Jason
A1 Ayouba, Ahidjo
A1 Rambaut, Andrew
A1 Delaporte, Eric
A1 Tessema, Sofonias
A1 D’Ortenzio, Eric
A1 Rimoin, Anne W.
A1 Hensley, Lisa E.
A1 Mbala-Kingebeni, Placide
A1 Peeters, Martine
A1 Ahuka-Mundeke, Steve
YR 2024
UL http://medrxiv.org/content/early/2024/08/22/2024.08.13.24311951.abstract
AB Background Recent reports raise concerns on the changing epidemiology of mpox in the Democratic Republic of the Congo (DRC), with increasing case counts, sexual contact-mediated clusters, and sustained human-to-human transmission driven by a novel monkeypox virus (MPXV) subclade, clade Ib. However, only a limited number of clade I MPXV genomes have been characterized so far, from a limited number of regions.Methods We conducted whole genome sequencing of 603 mpox-positive samples that were collected from 581 patients between 2018-2024 in 17 of the 26 provinces of the DRC.Results Genome coverage was at least 70% for 429/603 (71.1%) samples and near full-length MPXV genomes (>90% coverage) were obtained for 348/603 (57.7%) samples from 337 patients. All newly generated MPXV sequences belonged to clade I, among which 17 were clade Ib strains, all from patients infected in 2024 in the South-Kivu province. The large majority (>95%) of the new strains fall within previously described clade Ia groups and potential new groups have also been observed. The low number of APOBEC3 mutations found among clade Ia suggests that most human mpox cases are probably linked to zoonotic transmissions. Genetically diverse MPXV lineages co-circulate in small geographic areas during the same outbreak suggesting multiple zoonotic introductions over a short period from one or multiple reservoir species. Recent identification of mpox cases in Kinshasa shows that multiple lineages circulate in a large urban center, indicating separate introduction events.Conclusion The mpox epidemic in the DRC exhibits two distinct patterns. In traditional endemic regions, the epidemic is predominated by zoonotic spill-over events involving clade Ia. Conversely, in the eastern part of the country, the clade Ib outbreak is driven by human-to-human transmission highlighting the need for a coordinated response effort at the national, regional and international levels.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by Africa CDC Pathogen Genomics Initiative (Africa PGI) (Grants: INV-018278; INV-033857; Saving Lives and Livelihoods program; NU2HGH000077); Agence Francaise de Developpement through the AFROSCREEN project (grant agreement CZZ3209, coordinated by ANRS-MIE Maladies infectieuses emergentes in partnership with Institut de Recherche pour le Developpement (IRD) and Pasteur Institute); PANAFPOX project funded by ANRS-MIE ; Belgian Directorate-general Development Cooperation and Humanitarian Aid and the Research Foundation - Flanders (FWO, grant number G096222 N to L.L.); Department of Defense, Defense Threat Reduction Agency, Monkeypox Threat Reduction Network; USDA Non-Assistance Cooperative Agreement #20230048; International mpox Research Consortium (IMReC) through funding from the Canadian Institutes of Health Research and International Development Research Centre (grant no. MRR-184813); Wellcome Trust (Collaborators Award 206298/Z/17/Z, ARTIC network); E.L. received a PhD grant from the French Foreign Office.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics Committee of Kinshasa School of Public Health, University of Kinshasa (ESP-UNIKIN, Number ESP/CE/05/2023) gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors